10-Q: Intelligent Bio Solutions Q2 Revenue Jumps 47%, Raises $10M

Intelligent Bio Solutions Inc. reported a significant 47% revenue increase in Q2 2026, driven by new customers and re-orders, alongside a $10 million private placement, despite continued net losses and identified material weaknesses in internal controls.

Summary

• Revenue for the three months ended December 31, 2025, increased by 47.6% to $896,774 from $607,494 in the prior year.
• Gross profit for the three months ended December 31, 2025, more than doubled, increasing by 106.1% to $459,739 from $223,113 in the prior year.
• Gross margin improved to 48.69% for the three months ended December 31, 2025, up from 38.51% in the prior year, driven by operational efficiencies and capitalization of software development costs.
• Net loss for the three months ended December 31, 2025, increased to $(2,686,613) from $(2,256,797) in the prior year.
• The company completed a 1-for-10 reverse stock split on December 15, 2025, and regained Nasdaq compliance on January 7, 2026.
• A December Private Placement closed on January 2, 2026, raising approximately $10.0 million in gross proceeds through the sale of common stock and warrants.
• The company entered a strategic manufacturing partnership with Syrma Johari MedTech Ltd., expecting over 40% annual production cost savings and a 20 percentage point improvement in gross profit for its Intelligent Fingerprinting Drug Screening Reader.
• A strategic alliance with Vlepis Pty Ltd was formed to explore the consumer health monitoring market.
• Identified material weaknesses in internal control over financial reporting, with remediation efforts underway including the implementation of new accounting systems and additional finance personnel.
• The company has a substantial doubt about its ability to continue as a going concern for the next 12 months, requiring additional funding.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report with strong revenue and gross margin growth offset by increasing net losses, significant operational expenses, and a critical "going concern" warning, indicating ongoing financial instability despite successful capital raises.

Positives

• Revenue increased by 47.6% for the three months ended December 31, 2025, and 35.7% for the six months ended December 31, 2025, driven by 17 new customers in Q2 and 49 new customers in H1, and increased re-order rates for consumables.
• Gross profit more than doubled (106.1% increase) for the three months ended December 31, 2025, and increased by 71.6% for the six months ended December 31, 2025.
• Gross margin improved significantly to 48.69% from 38.51% in the prior-year quarter, attributed to operational efficiencies and a more favorable sales mix.
• Contribution margin (non-GAAP) improved by 3.36 percentage points to 74.48% for the three months ended December 31, 2025, and by 5.82 percentage points to 73.17% for the six months ended December 31, 2025, due to improved production efficiency and sales mix.
• Secured a new strategic manufacturing partnership with Syrma Johari MedTech Ltd., projected to yield over 40% annual production cost savings and approximately 20 percentage points improvement in gross profit for the Intelligent Fingerprinting Drug Screening Reader.
• Formed a strategic alliance with Vlepis Pty Ltd to enter the consumer health monitoring market, leveraging R&D and expanding distribution networks.
• Announced a major new contract with one of the United Kingdom's largest industrial service providers in October 2025.
• Successfully regained compliance with Nasdaq's minimum bid price requirement following a 1-for-10 reverse stock split.
• Successfully raised approximately $10.0 million in gross proceeds from a private placement in December 2025, with cash received in January 2026.
• Raised additional $1,044,337 (net) in January 2026 from warrant exercises.

Negatives

• Net loss increased to $(2,686,613) for the three months ended December 31, 2025, from $(2,256,797) in the prior year, and to $(5,681,605) for the six months ended December 31, 2025, from $(4,951,596) in the prior year.
• Selling, general and administrative expenses increased by $527,927 (29.2%) for the three months and $1,238,735 (33.0%) for the six months ended December 31, 2025, primarily due to increased marketing, wages, and legal expenses.
• Government support income decreased by $60,920 for the three months ended December 31, 2025, due to changes in U.K. R&D tax credit legislation (reducing benefit from 14.5% to 10%).
• Incurred impairment of long-lived assets of $27,147 for the three months and $288,927 for the six months ended December 31, 2025, related to construction in progress assets held for sale.
• Interest expense increased significantly by $42,707 for the three months and $24,283 for the six months ended December 31, 2025, due to new lease agreements and notes payable.
• Interest income decreased by $16,603 for the three months and $60,939 for the six months ended December 31, 2025, due to spending of funds from capital raising activities.
• The company has an accumulated deficit of $68,193,661 as of December 31, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern for the next 12 months, necessitating further capital raises.
• A repayment obligation of $2,096,222 to the Australian Government for a grant remains outstanding.

Risks

• Inability to raise additional capital to fund operations, potentially leading to delays, reductions, or cessation of operations, or forced asset sales.
• Financing terms, if available, may be unfavorable or lead to significant dilution of stockholders' equity.
• Potential delisting from Nasdaq if continued listing requirements are not met, despite regaining compliance with the minimum bid price rule.
• Extended delays or unfavorable licensing terms for the Biosensor IP with the University of Newcastle due to the liquidation of Life Science Biosensor Diagnostics Pty Ltd (LSBD), postponing further development of the BPT.
• Inability to repay the $2,096,222 Australian Government Grant when due, potentially resulting in defaults, acceleration of amounts owed, penalties, or enforcement actions.
• Changes in government funding levels, staffing resources, or policy priorities at regulatory agencies (e.g., FDA, SEC) could adversely affect their ability to perform regulatory and oversight functions, leading to delays in product approvals.
• Loss of emerging growth company status at the end of the current fiscal year (June 30, 2026) will increase reporting and compliance obligations, potentially making financial statements less comparable to other public companies.

Future Outlook

The company expects to continue incurring operating losses for the foreseeable future and does not anticipate generating positive cash flows from operating activities in the near term. Profitability depends on successful regulatory approvals (e.g., FDA 510(k) submission), expansion into target markets, and continued product development and commercialization. Development and regulatory expenses are expected to increase as the company gathers data for its FDA 510(k) submission. Management intends to further enhance strategic sales mix and optimize operational processes to continue driving sustainable gross profit improvement.

Management Comments

• "Management believes there is a material risk that the Company's cash and cash equivalents of approximately $740,371 and the subscription receivable from shareholders of $9,402,105 (which, on January 2, 2026, the proceeds were received by the Company) as of December 31, 2025 will be insufficient to fund its current operating plan for at least the next 12 months from the issuance date of these unaudited condensed consolidated financial statements."
• "We expect this trend [revenue increase] to continue as we expand into new markets in the future."
• "Management intends to further enhance strategic sales mix and optimize operational processes to continue driving sustainable gross profit improvement."
• "We expect development and regulatory expenses to increase in future periods as the Company continues to work to gather additional supporting data to strengthen its new 510(k) submission to the FDA."
• "Management is committed to continuing the steps necessary to remediate the control deficiencies that constituted the above material weaknesses."

Industry Context

StockSavvy.ai notes that Intelligent Bio Solutions operates in the competitive medical technology sector, specifically in rapid, non-invasive testing. The strategic manufacturing partnership with Syrma Johari MedTech Ltd. and the alliance with Vlepis Pty Ltd indicate a focus on cost optimization and market expansion into consumer health monitoring, aligning with broader industry trends towards efficiency and diversified product portfolios. The continued investment in R&D for FDA 510(k) submission highlights the regulatory hurdles and capital intensity typical for medical device companies seeking to penetrate major markets like the U.S.

Comparison to Industry Standards

• The reported gross margin of 48.69% for the quarter, while an improvement, is still below the average for established medical device companies, which often see gross margins in the 60-80% range. For example, a company like Abbott Laboratories typically reports gross margins above 55-60%, and specialized diagnostic companies can exceed 70%. The projected 20 percentage point improvement from the new manufacturing partnership could bring the company closer to industry averages.
• The significant net losses and ongoing "going concern" warning indicate a pre-profitability stage common for early-to-mid-stage medical technology companies, but the magnitude of the accumulated deficit ($68.2 million) suggests a prolonged period of investment without commensurate returns compared to more mature industry players.
• The reliance on equity financing and warrant exercises for liquidity is typical for growth-stage medtech firms, but the frequency and size of capital raises, coupled with the "going concern" warning, suggest a higher burn rate relative to available capital compared to more financially stable peers.

Corporate Governance

Legal Proceedings

• The company is not currently engaged in any material legal proceedings.
• From time to time, the company may become a party to various legal proceedings arising in the ordinary course of business.

Stakeholder Impact

• Shareholders: Potential for significant dilution from future equity financings; risk of delisting if Nasdaq requirements are not met; uncertainty regarding the value and liquidity of common stock due to loss of emerging growth company status.
• Employees: Increased staffing in marketing and finance departments; potential impact on R&D staff due to postponed BPT development.
• Customers: Expansion into new markets and customer segments (e.g., UK industrial services, major sporting organizations, law enforcement, commercial airlines) aims to increase product availability and service.
• Suppliers: New strategic manufacturing partnership with Syrma Johari MedTech Ltd. is expected to improve cost efficiency. Reliance on major suppliers (29.1% of purchases in Q2 2026) presents concentration risk.
• Creditors: Risk of default on the $2,096,222 Australian Government Grant repayment if additional financing is not secured.

Next Steps

• Continue efforts to gather additional supporting data to strengthen the new 510(k) submission to the FDA.
• Initiate research aimed at broadening the capabilities of the Intelligent Fingerprinting System to test for additional drugs and indications.
• Expand the Intelligent Fingerprinting System into new customer segments, including major sporting organizations, law enforcement, and commercial airlines.
• Develop a strategic network of distributors throughout the APAC Region, Europe, and North America.
• Continue to implement new accounting systems for the subsidiary Intelligent Fingerprinting Limited, with planned completion by the third quarter of fiscal 2026.
• Recruit additional financial reporting and accounting personnel with adequate knowledge of US GAAP and SEC rules.
• Engage outside consultants to assist in the evaluation of the design, implementation, and documentation of internal controls.
• Obtain additional funding through equity or debt financings, strategic collaborations, or other arrangements to address liquidity concerns.
• Finalize appropriate licensing arrangements related to the Biosensor Platform Technology (BPT) with the University of Newcastle.

Key Dates

Recommendation

While Intelligent Bio Solutions Inc. demonstrates strong revenue growth and improved gross margins, indicating market traction for its fingerprinting platform, the persistent and increasing net losses, coupled with the explicit "going concern" warning, present significant financial instability. The successful capital raises provide short-term liquidity but highlight ongoing cash burn. The identified material weaknesses in internal controls and the delay in Biosensor IP licensing add layers of operational and strategic risk. A "hold" recommendation is appropriate for investors who are already exposed and believe in the long-term potential of the technology, but new investors should exercise extreme caution due to the high risk profile and the need for continuous capital infusion. The company needs to demonstrate a clear path to profitability and resolve its going concern issues before a more positive outlook can be justified.

Keywords

Medical Technology, Drug Screening, Fingerprint Testing, Non-invasive Diagnostics, SEC Filing, 10-Q, Financial Results, Biotechnology, Nasdaq Compliance, Capital Raise, Going Concern, Intelligent Bio Solutions